product summary
Loading...
company name :
Sino Biological
product type :
protein
product name :
Influenza A H1N1 (A/California/07/2009) Hemagglutinin / HA Protein (His Tag)
catalog :
11085-V08H
quantity :
100 µg
price :
348 USD
more info or order :
Sino Biological product webpage
citations: 17
Published Application/Species/Sample/DilutionReference
  • ELISA; H1N1 subtype
de Silva T, Gould V, Mohammed N, Cope A, Meijer A, Zutt I, et al. Comparison of mucosal lining fluid sampling methods and influenza-specific IgA detection assays for use in human studies of influenza immunity. J Immunol Methods. 2017;449:1-6 pubmed publisher
Hinke D, Andersen T, Gopalakrishnan R, Skullerud L, Werninghaus I, Gr xf8 deland G, et al. Antigen bivalency of antigen-presenting cell-targeted vaccines increases B cell responses. Cell Rep. 2022;39:110901 pubmed publisher
Jeong H, Lee C, Lee J, Lee J, Hwang H, Lee M, et al. Hemagglutinin Nanoparticulate Vaccine with Controlled Photochemical Immunomodulation for Pathogenic Influenza-Specific Immunity. Adv Sci (Weinh). 2021;8:e2100118 pubmed publisher
Andersen T, Bodin J, Oftung F, Bogen B, Mjaaland S, Grødeland G. Pandemic Preparedness Against Influenza: DNA Vaccine for Rapid Relief. Front Immunol. 2021;12:747032 pubmed publisher
Lopez E, Haycroft E, Adair A, Mordant F, O Neill M, Pymm P, et al. Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 variants via multiplex assay. JCI Insight. 2021;6: pubmed publisher
Jung J, Mundle S, Ustyugova I, Horton A, Boutz D, Pougatcheva S, et al. Influenza vaccination in the elderly boosts antibodies against conserved viral proteins and egg-produced glycans. J Clin Invest. 2021;131: pubmed publisher
Vuorela A, Freitag T, Leskinen K, Pessa H, Harkonen T, Stracenski I, et al. Enhanced influenza A H1N1 T cell epitope recognition and cross-reactivity to protein-O-mannosyltransferase 1 in Pandemrix-associated narcolepsy type 1. Nat Commun. 2021;12:2283 pubmed publisher
Nakakita S, Sriwilaijaroen N, Suzuki Y, Hirabayashi J. Preparation and Detection of Glycan-Binding Activity of Influenza Virus. Methods Mol Biol. 2020;2132:567-583 pubmed publisher
Ramírez Salinas G, García Machorro J, Rojas Hernández S, Campos Rodríguez R, De Oca A, Gomez M, et al. Bioinformatics design and experimental validation of influenza A virus multi-epitopes that induce neutralizing antibodies. Arch Virol. 2020;165:891-911 pubmed publisher
Horns F, Dekker C, Quake S. Memory B Cell Activation, Broad Anti-influenza Antibodies, and Bystander Activation Revealed by Single-Cell Transcriptomics. Cell Rep. 2020;30:905-913.e6 pubmed publisher
Handumrongkul C, Ye A, Chmura S, Soroceanu L, Mack M, Ice R, et al. Durable multitransgene expression in vivo using systemic, nonviral DNA delivery. Sci Adv. 2019;5:eaax0217 pubmed publisher
Vono M, Eberhardt C, Auderset F, Mastelic Gavillet B, Lemeille S, Christensen D, et al. Maternal Antibodies Inhibit Neonatal and Infant Responses to Vaccination by Shaping the Early-Life B Cell Repertoire within Germinal Centers. Cell Rep. 2019;28:1773-1784.e5 pubmed publisher
Jacquet N, Navarre C, Desmecht D, Boutry M. Hydrophobin fusion of an influenza virus hemagglutinin allows high transient expression in Nicotiana benthamiana, easy purification and immune response with neutralizing activity. PLoS ONE. 2014;9:e115944 pubmed publisher
Gopinath S, Awazu K, Fujimaki M, Shimizu K. Neu5Ac?2,6Gal and Neu5Ac?2,3Gal receptor specificities on influenza viruses determined by a waveguide-mode sensor. Acta Biomater. 2013;9:5080-7 pubmed publisher
Fang Y, Banner D, Kelvin A, Huang S, Paige C, Corfe S, et al. Seasonal H1N1 influenza virus infection induces cross-protective pandemic H1N1 virus immunity through a CD8-independent, B cell-dependent mechanism. J Virol. 2012;86:2229-38 pubmed publisher
Gupta N, Tomar P, Sharma V, Dixit V. Development and characterization of chitosan coated poly-(?-caprolactone) nanoparticulate system for effective immunization against influenza. Vaccine. 2011;29:9026-37 pubmed publisher
Ackerman M, Moldt B, Wyatt R, Dugast A, McAndrew E, Tsoukas S, et al. A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. J Immunol Methods. 2011;366:8-19 pubmed publisher
image
image 1 :
Sino Biological 11085-V08H image 1
product information
Catalog Number :
11085-V08H
Product Name :
Influenza A H1N1 (A/California/07/2009) Hemagglutinin / HA Protein (His Tag)
Product Type :
Protein
Host Species :
HEK293 Cells
Conjugation :
C-His
Size :
100 µg
List Price :
348 USD
Gene ID :
ACP41953.1
Product Description :
A DNA sequence encoding the extracellular domain of Influenza A virus H1N1 (A/California/07/2009) (ACP41953.1) hemagglutinin (Met1-Gln529) (HA1+HA2, uncleaved) was fused with a polyhistidine tag at the C-terminus.
SpeciesSummary :
H1N1
ALTnames :
HA
Purity :
> 95 % as determined by SDS-PAGE.
Buffer :
Lyophilized from sterile PBS, pH 7.4.
Packaging :
In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature. Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Storage :
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
more info or order :
Sino Biological product webpage
company information
Sino Biological
Building 9, No.18 Kechuang 10th St, BDA, Beijing, 100176
marketing@sinobiological.com
https://www.sinobiological.com
86 400-890-9989
headquarters: China
Sino Biological is an international reagent supplier and service provider. The company specializes in recombinant protein production and antibody development. All of Sino Biological's products are independently developed and produced, including recombinant proteins, antibodies and cDNA clones. Sino Biological is the researchers' one-stop technical services shop for the advanced technology platforms they need to make advancements. In addition, Sino Biological offer pharmaceutical companies and biotechnology firms pre-clinical production technology services for hundreds of monoclonal antibody drug candidates.